M&A Deal Summary

Illumina Acquires Epicentre Biotechnologies

On January 11, 2011, Illumina acquired life science company Epicentre Biotechnologies

Acquisition Highlights
  • This is Illumina’s 1st transaction in the Life Science sector.
  • This is Illumina’s 3rd transaction in the United States.
  • This is Illumina’s 1st transaction in Wisconsin.

M&A Deal Summary
Date 2011-01-11
Target Epicentre Biotechnologies
Sector Life Science
Buyer(s) Illumina
Deal Type Add-on Acquisition

Target

Epicentre Biotechnologies

Madison, Wisconsin, United States
Epicentre Biotechnologies, Inc. is a provider of nucleic acid sample preparation reagents and specialty enzymes used in sequencing and microarray applications.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Illumina

San Diego, California, United States
Category Company
Founded 1998
Sector Life Science
Employees10,590
Revenue 4.5B USD (2023)
DESCRIPTION
Entrance to Illumina's corporate headquarters in San Diego, California.
Entrance to Illumina's corporate headquarters in San Diego, California.

Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. Illumina provides innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. The Company's customers include genomic research centers, academic institutions, government laboratories, hospitals, and reference laboratories as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic, and consumer genomics companies. Illumina was formed in 1998 and is based in San Diego, California.

DEAL STATS #
Overall 3 of 29
Sector (Life Science) 1 of 18
Type (Add-on Acquisition) 3 of 14
State (Wisconsin) 1 of 1
Country (United States) 3 of 20
Year (2011) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2010-07-27 Helixis

Carlsbad, California, United States

Helixis, Inc. is a developer of low cost molecular diagnostic products.

Buy $105M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2012-09-19 BlueGnome

Cambridge, United Kingdom

BlueGnome Ltd. is a provider of solutions for the screening of genetic abnormalities associated with developmental delay, cancer, and infertility.

Buy -
Mergr

Product

Company

Legal